On Wednesday, Following U.S. Stocks were among the “Top Gainers”: Amicus Therapeutics, (NASDAQ:FOLD), Callon Petroleum, (NYSE:CPE), Denbury Resources, (NYSE:DNR), SM Energy, (NYSE:SM)

Amicus Therapeutics, (NASDAQ:FOLD), with shares inclined 5.32%, closed at $9.31.

Callon Petroleum, (NYSE:CPE), with shares jumped 5.18%, settled at $6.50.

Denbury Resources, (NYSE:DNR), with shares climbed 4.91%, and closed at $7.91.

SM Energy, (NYSE:SM), surged 4.87%, and closed at $44.83.

Latest NEWS regarding these Stocks are depicted underneath:

Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Formerly on March 3, Amicus Therapeutics, Inc. (FOLD), a biopharmaceutical corporation at the forefront of therapies for rare and orphan diseases, declared financial results for the full-year ended December 31, 2014. The Corporation also offered program updates and reiterated full-year 2015 net cash spend guidance.

Financial Highlights for Full Year Quarter Ended December 31, 2014:

• Cash, cash equivalents, and marketable securities totaled $169.1 million at December 31, 2014 contrast to $82.0 million at December 31, 2013.
• Total operating expenses raised to $69.9 million contrast to $64.5 million for the full-year 2013 primarily due to raises in preclinical and clinical development costs on the Fabry monotherapy and Pompe programs.
• Net cash spend was $53.2 million, below the full-year 2014 guidance range of $54-59 million.
• Net loss was $68.9 million, or $0.93 per share, contrast to a net loss of $59.6 million, or $1.16 per share, for the full-year 2013.

2015 Financial Guidance:

Cash, cash equivalents, and marketable securities totaled $169.1 million at December 31, 2014 contrast to $82.0 million at December 31, 2013. The Corporation’s balance sheet was strengthened during 2014 with a $40 million at-the-market (ATM) financing in addition to a $103.5 million public offering. Amicus anticipates full-year 2015 net cash spend between $73 million and $83 million. The current cash position is projected to fund operations into 2017.

Amicus Therapeutics, Inc., a biopharmaceutical corporation, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases.

Callon Petroleum Corporation (NYSE:CPE)

Callon Petroleum Corporation (CPE), declared that it has priced an underwritten public offering of 9,000,000 shares of its ordinary stock for total estimated gross proceeds (before the underwriter’s discounts and commissions and estimated offering expenses) of about $59 million. The underwriter will have an option to purchase up to an additional 1,350,000 shares of ordinary stock from the Corporation. The offering is predictable to close on or about March 13, 2015.

Callon intends to use the net proceeds from this offering to repay amounts outstanding under its credit facility, with any remainder being used for general corporate purposes, which may comprise funding of its capital program and future attainments.

J.P. Morgan is acting as sole book-running manager for the offering.

Callon Petroleum Corporation engages in the exploration, development, attainment, and production of oil and natural gas properties in the Permian Basin in West Texas.

Denbury Resources Inc. (NYSE:DNR)

Formerly on February 19, Denbury Resources Inc. (DNR), declared adjusted net revenue (a non-GAAP measure) of $93 million for the fourth quarter of 2014, or $0.27 per diluted share. On a GAAP basis, the Corporation recorded quarterly net revenue of $364 million, or $1.04 per diluted share, on quarterly proceeds of $480 million. Adjusted net revenue for the fourth quarter of 2014 differs from GAAP net revenue primarily due to the exclusion of a $451 million (pre-tax) gain on noncash fair value adjustments on commodity derivatives (a non-GAAP measure).

Adjusted net revenue for the fourth quarter of 2014 raised by $2 million on a sequential-quarter basis and reduced by $7 million when contrast to the preceding-year fourth quarter. The change as compared to preceding-year was primarily due to 2014 fourth quarter decreases in oil proceeds as a result of lower realized prices and raises in depletion, depreciation and amortization (“DD&A”), largely offset by settlements on our commodity derivatives and lower lease operating expenses.

Denbury’s full-year 2014 adjusted net revenue was $365 million, or $1.04 per diluted share. On a GAAP basis, the Corporation recorded full-year 2014 net revenue of $635 million, or $1.81 per diluted share, on annual proceeds of $2.4 billion. Adjusted net revenue for the full-year 2014 differs from GAAP net revenue for the year primarily due to the exclusion of a $554 million (pre-tax) gain on noncash fair value adjustments on commodity derivatives, and the exclusion of a $114 million (pre-tax) loss on the early extinguishment of debt. Adjusted net revenue for full-year 2014 reduced by $174 million contrast to the same measure in 2013, primarily due to decreases in oil proceeds as a result of lower realized prices, in addition to raises in DD&A, interest expense, and lease operating expenses in the same year.

Denbury Resources Inc. operates as an independent oil and natural gas corporation in the United States. The corporation primarily focuses on improved oil recovery utilizing carbon dioxide.

SM Energy Corporation (NYSE:SM)

Formerly on february 24, SM Energy Corporation (SM), provided 2015 capital, production, and performance guidance, provided an update on the Corporation’s operating activities, and reports financial results for the fourth quarter of 2014.

FOURTH QUARTER 2014 RESULTS:

SM Energy posted GAAP net revenue for the fourth quarter of 2014 of $331.7 million, or $4.91 per diluted share, contrast to net revenue of $7.0 million, or $0.10 per diluted share, for the same period of 2013. Adjusted net revenue for the fourth quarter was $70.9 million, or $1.05 per diluted share, contrast to adjusted net revenue of $85.9 million, or $1.26 per adjusted diluted share, in the same period of 2013. Adjusted net revenue excludes certain items that the Corporation believes affect the comparability of operating results. Items excluded are generally one-time items or are items whose timing and/or amount cannot be reasonably estimated. Earnings before interest, taxes, depreciation, depletion, amortization, accretion, and exploration expense (“adjusted EBITDAX”) were $419.0 million for the fourth quarter of 2014, an raise of 6% from $395.5 million for the same period in 2013.

Adjusted net revenue and adjusted EBITDAX are non-GAAP financial measures; please refer to the reconciliations in the accompanying Financial Highlights section at the end of this release for additional information about these measures.

SM Energy had average daily production of 176 MBOE/d for the fourth quarter of 2014. The production mix for the quarter was 32% oil/condensate, 45% gas, and 23% NGLs.

SM Energy Corporation, an independent energy corporation, engages in the attainment, exploration, development, and production of crude oil and condensate, natural gas, and natural gas liquids in onshore North America.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.